NEOVASCULAR AGE RELATED MACULAR DEGENERATION

This study looked at how much of the drug aflibercept gets into the blood when a high dose (8 mg) is injected into both eyes of people with diabetic macular edema or wet age-related macular degeneration. Fifty-one adults received the injections and had blood samples taken to meas…

This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug migh…

This study looked at the long-term safety of faricimab, a medicine injected into the eye, for people with wet age-related macular degeneration (a leading cause of vision loss). Over 1000 adults who had already completed earlier faricimab studies took part. The main goal was to tr…

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and help maintain or improve vision. Participants received the eye drops and were monitored for changes in eyesight…

This early-stage study tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to check the drug's safety and find the best dose for future studies. Participants received the drug by injectio…

This study tested a new medicine called LUBT010 against a standard treatment (Lucentis) for wet age-related macular degeneration, a leading cause of vision loss. About 600 adults aged 50 and older received monthly eye injections for one year. The main goal was to see if LUBT010 w…

This study tested whether a new drug called FYB203 works as well as the standard treatment Eylea for wet age-related macular degeneration, a condition that causes vision loss. 434 adults aged 50 and older took part. The main goal was to see if vision improved after 8 weeks of tre…

This study measured the thickness of the conjunctiva and Tenon's capsule (parts of the eye) in 736 people with neovascular age-related macular degeneration or diabetic macular edema, and in healthy volunteers of similar age. Researchers used a special imaging device (SD-OCT) to t…